If you have just signed up to OnMedica, you are seeing this message because we couldn’t automatically verify that you are a practising doctor in the UK. Please check your email inbox as we may need a few more details to validate your OnMedica membership. If you haven’t received an email from us or you need assistance, please contact firstname.lastname@example.org.
Choose a social network to share with, or copy the shortened URL to share elsewhere
From 20th December, the monoclonal antibody sotrovimab will be available for use as a first line treatment for non-hospitalised patients who are PCR positive and aged 12 and above who are considered at highest risk of progression to severe disease, hospital admission or death.
Customise your preferences for any tracking technology
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to deliver personalized marketing content and to operate, serve and track ads.
These trackers help us to deliver personalized marketing content to you based on your behaviour and to operate, serve and track social advertising.
These trackers help us to measure traffic and analyze your behaviour with the goal of improving our service.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.